Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

N. Ånensen; S. M. Hjelle; W. Van Belle; I. Haaland; E. Silden; J.-C. Bourdon; R. Hovland; K. Taskén; S. Knappskog; P.E. Lønning; O. Bruserud; B. T. Gjertsen

doi:10.1038/onc.2011.348

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

N. Ånensen, S. M. Hjelle, W. Van Belle, I. Haaland, E. Silden, J.-C. Bourdon, R. Hovland, K. Taskén, S. Knappskog, P.E. Lønning, O. Bruserud, B. T. Gjertsen

Research output: Contribution to journal › Article › peer-review

57 Citations (Scopus)

Abstract

The wild-type tumor-suppressor gene TP53 encodes several isoforms of the p53 protein. However, while the role of p53 in controlling normal cell cycle progression and tumor suppression is well established, the clinical significance of p53 isoform expression is unknown. A novel bioinformatic analysis of p53 isoform expression in 68 patients with acute myeloid leukemia revealed distinct p53 protein biosignatures correlating with clinical outcome. Furthermore, we show that mutated FLT3, a prognostic marker for short survival in AML, is associated with expression of full-length p53. In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms ? and ? expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication. © 2012 Macmillan Publishers Limited All rights reserved.

Original language	English
Pages (from-to)	1533-1545
Number of pages	13
Journal	Oncogene
Volume	31
Issue number	12
DOIs	https://doi.org/10.1038/onc.2011.348
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/onc.2011.348

Cite this

@article{4dd62a7e037947dc8942a4508ddcb51e,

title = "Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia",

abstract = "The wild-type tumor-suppressor gene TP53 encodes several isoforms of the p53 protein. However, while the role of p53 in controlling normal cell cycle progression and tumor suppression is well established, the clinical significance of p53 isoform expression is unknown. A novel bioinformatic analysis of p53 isoform expression in 68 patients with acute myeloid leukemia revealed distinct p53 protein biosignatures correlating with clinical outcome. Furthermore, we show that mutated FLT3, a prognostic marker for short survival in AML, is associated with expression of full-length p53. In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms ? and ? expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication. {\textcopyright} 2012 Macmillan Publishers Limited All rights reserved.",

author = "N. {\AA}nensen and Hjelle, {S. M.} and {Van Belle}, W. and I. Haaland and E. Silden and J.-C. Bourdon and R. Hovland and K. Task{\'e}n and S. Knappskog and P.E. L{\o}nning and O. Bruserud and Gjertsen, {B. T.}",

note = "MEDLINE{\textregistered} is the source for the MeSH terms of this document.",

year = "2012",

doi = "10.1038/onc.2011.348",

language = "English",

volume = "31",

pages = "1533--1545",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "12",

}

TY - JOUR

T1 - Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

AU - Ånensen, N.

AU - Hjelle, S. M.

AU - Van Belle, W.

AU - Haaland, I.

AU - Silden, E.

AU - Bourdon, J.-C.

AU - Hovland, R.

AU - Taskén, K.

AU - Knappskog, S.

AU - Lønning, P.E.

AU - Bruserud, O.

AU - Gjertsen, B. T.

N1 - MEDLINE® is the source for the MeSH terms of this document.

PY - 2012

Y1 - 2012

N2 - The wild-type tumor-suppressor gene TP53 encodes several isoforms of the p53 protein. However, while the role of p53 in controlling normal cell cycle progression and tumor suppression is well established, the clinical significance of p53 isoform expression is unknown. A novel bioinformatic analysis of p53 isoform expression in 68 patients with acute myeloid leukemia revealed distinct p53 protein biosignatures correlating with clinical outcome. Furthermore, we show that mutated FLT3, a prognostic marker for short survival in AML, is associated with expression of full-length p53. In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms ? and ? expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication. © 2012 Macmillan Publishers Limited All rights reserved.

AB - The wild-type tumor-suppressor gene TP53 encodes several isoforms of the p53 protein. However, while the role of p53 in controlling normal cell cycle progression and tumor suppression is well established, the clinical significance of p53 isoform expression is unknown. A novel bioinformatic analysis of p53 isoform expression in 68 patients with acute myeloid leukemia revealed distinct p53 protein biosignatures correlating with clinical outcome. Furthermore, we show that mutated FLT3, a prognostic marker for short survival in AML, is associated with expression of full-length p53. In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms ? and ? expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication. © 2012 Macmillan Publishers Limited All rights reserved.

UR - http://www.scopus.com/inward/record.url?scp=84858798570&partnerID=8YFLogxK

U2 - 10.1038/onc.2011.348

DO - 10.1038/onc.2011.348

M3 - Article

C2 - 21860418

SN - 0950-9232

VL - 31

SP - 1533

EP - 1545

JO - Oncogene

JF - Oncogene

IS - 12

ER -

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this